Company news

MediWound Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

MediWound Announces Closing of the Concurrent Registered Direct and Private Placement Offerings

October 6, 2022

MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million

September 21, 2022

EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

September 19, 2022

MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

September 11, 2022

MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates

August 8, 2022

MediWound Enhances Its Board and Executive Leadership Team

August 7, 2022

MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns

August 2, 2022

MediWound Schedules Second Quarter 2022 Financial Results

July 31, 2022

MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

July 10, 2022

MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13

July 7, 2022

MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers

July 6, 2022

MediWound Names Mr. Tzvi Palash as Chief Operating Officer

June 29, 2022

MediWound Reports First Quarter 2022 Financial Results

May 16, 2022

MediWound Announces CEO Transition

May 16, 2022

MediWound Announces Positive Results from Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

May 11, 2022

MediWound to Report First Quarter Financial Results and Host a Conference Call and Webcast on May 17, 2022

May 9, 2022

MediWound to Present EscharEx Clinical Data at the Symposium on Advanced Wound Care (SAWC) Spring 2022

March 28, 2022

MediWound Announces Exercise of Over-Allotment Option

March 21, 2022

MediWound Announces Last Patient Out in EscharEx U.S. Phase 2 Trial for the Debridement of Chronic Wounds

March 20, 2022

MediWound Reports Fourth Quarter and Full Year 2021 Financial Results

March 16, 2022

MediWound Announces Closing of Public Offering of Ordinary Shares

March 9, 2022

MediWound Announces Pricing of Public Offering of Ordinary Shares

March 2, 2022

MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares

March 1, 2022

MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army

February 16, 2022

MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol

February 9, 2022

MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds

January 23, 2022

MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds

December 19, 2021

MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study

December 5, 2021

MediWound Reports Third Quarter 2021 Financial Results

November 15, 2021

MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021

November 3, 2021

MediWound Announces Peer-Reviewed Publication of EscharEx In-Vivo Head-to-Head Comparator Study in the Journal of Wound Care

October 3, 2021

MediWound Reports Second Quarter Financial Results

August 9, 2021

MediWound to Report Second Quarter 2021 Financial Results and Host a Conference Call and Webcast on August 10, 2021

August 1, 2021

MediWound Announces Positive Outcome of Interim Assessment for its EscharEx U.S. Phase 2 Adaptive Design Study

July 27, 2021

MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma

July 25, 2021

MediWound Announces Positive Topline Results from Phase 3 Pediatric Study (CIDS) of NexoBrid for Eschar Removal of Severe Thermal Burns

July 19, 2021

MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal

July 8, 2021

MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid Biologics License Application

June 28, 2021

MediWound Completes Patient Enrollment for Interim Assessment of its U.S. EscharEx Phase 2 Adaptive Design Study

June 8, 2021

MediWound Reports First Quarter 2021 Financial Results

May 4, 2021

MediWound to Report First Quarter 2021 Financial Results and Host a Conference Call and Webcast on May 5, 2021

April 25, 2021

MediWound Enrolls First Patient in Phase 2 Pharmacology Study of EscharEx

April 21, 2021

MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results

February 24, 2021

MediWound Launches Clinical Development Program for Treatment of Non-Melanoma Skin Cancer

February 21, 2021

MediWound Provides Progress Update on Its EscharEx Clinical Development Program

January 10, 2021

Successful Completion of In-Vivo Head-to-Head Comparator Study of EscharEx versus a Commercial Enzymatic Debridement Agent

December 20, 2020

MediWound Continues Global Expansion with Distribution Agreement for NexoBrid in United Arab Emirates with Ghassan Aboud Group

December 13, 2020

MediWound Reports Third Quarter 2020 Financial Results

November 9, 2020

MediWound to Report Third Quarter 2020 Financial Results and Host a Conference Call and Webcast on November 10, 2020

November 1, 2020

MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study

October 27, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 24 calls. Every call is listed under its year.

Decks

The 5 newest of 15 decks. Every deck is listed under its year.